More Is Better, Right? Panel vs. Targeted Testing

 

There has been rapid evolution in genetic testing from simple single gene markers to now a whole “omic” approach fueled largely by rapid technological advancements, followed by the completion of Human Genome Project. This talk will explore some of the advances in genetic/genomic testing and efforts to evaluate evidence and to standardize testing as well as exploring the future of genomic testing.

Originally published on July 6, 2023

Lecture Presenter

Victoria M. Pratt, PhD, FACMG

Victoria M. Pratt, PhD, FACMG

Vice President, Molecular Diagnostics Quality Assessments
Optum Genomics

Dr. Pratt is a medical and clinical molecular geneticist board-certified by the American College of Medical Genetics. Prior to joining Optum Genomics, she was the Laboratory Director of Pharmacogenomics and Molecular Genetics at the Indiana University School of Medicine. She continues to be adjunct professor of medical and molecular genetics at Indiana University.

Dr. Pratt is the past president of the association for Molecular Pathology. Dr. Pratt continues to serve on the CDC Genetic Testing Reference Materials (GeT-RM) Coordination Program, which coordinates reference materials for molecular genetics; the National Academy of Medicine’s Roundtable on Genomics and Precision Health; and the American Medical Association’s (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory Committee.

Dr. Pratt graduated with a PhD in medical and molecular genetics from Indiana University School of Medicine. Her fellowship training was in PhD medical and clinical molecular genetics at Henry Ford Hospital, Detroit.

Objectives

After this presentation, participants will be able to:

  • Understand the evolution of genomic testing
  • Differentiate evidence of genes included in genomic panel testing
  • Describe standardization efforts for pharmacogenomic tests

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories